Morningstar

Haleon Cuts Guidance After Cough Medication Sales Drop

Provided by Dow Jones

By Aimee Look 




  Advil-maker Haleon cut its outlook for the year, as lower sales of its cough and cold medications weighed on results. 



  The company, which spun out of pharmaceutical group GSK in 2022, said it now expects full-year organic revenue growth at 2.5%. Haleon at its half-year results in July said it expected organic revenue growth of 3% to 5% for the full year. 



  The British consumer healthcare company said that it faced weaker consumption for cough, cold and flu products in the quarter. Its respiratory health category had a 2% fall in organic revenue. 



  At the same time, its oral health category grew 8.8% organically for the quarter. 



  Also on Thursday, Haleon reported an overall rise in organic revenue, booking 2.87 billion pounds, equivalent to $3.82 billion. On an organic basis, revenue grew 2.6% on year for the quarter. 





  Write to Aimee Look at aimee.look@wsj.com 





  (END) Dow Jones Newswires



  October 29, 2026 03:36 ET (07:36 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
5 Stocks to Buy Trading at Big Discounts
 
Plus, what recent bond market volatility means for investors. 
 
 
David Sekera, CFA and Sarah Hansen 
 
 
 
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
 
Defense spending and booming data center demand could provide powerful tailwinds for these 4-star stocks. 
 
 
David Sekera, CFA, Sarah Hansen, and Jess Bebel 
 
 
 
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
 
Despite a looming patent cliff, a strong drug pipeline and 4.1% yield give investors reasons for optimism. 
 
 
Karen Andersen, CFA 
 
 
 
What 7 Key Market Indicators Are Telling Investors Right Now
 
US equity valuations have retreated from their recent highs, but all 7 major market indicators remain above their long-term averages. 
 
 
Amy C. Arnott, CFA 
 
 
 
There Are Three Paths Forward for the AI Boom. Two of Them Lead to Lower Interest Rates
 
Mass layoffs or a spending slowdown would likely require hefty Fed rate cuts. 
 
 
Preston Caldwell 
 
 
 
 

			Sponsor Center